2PQ.DU Stock Analysis
2P
Uncovered
Organogenesis Holdings Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Market cap $B
0.386
Dividend yield
—
Shares outstanding
131.18 B
Organogenesis Holdings, Inc. is a regenerative medical company. The company is headquartered in Canton, Massachusetts and currently employs 1,030 full-time employees. The company went IPO on 2016-12-02. The company offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier for a variety of wound types, and the Affinity, Novachor and NuShield wound coverings to address a variety of wound sizes and types. Its sports medicine products include NuShield for surgical application in soft tissue repairs, and Affinity, Novachor and PuraPly AM for management of open wounds in the surgical setting. The company offers its products to a range of healthcare customers, including hospitals, wound care centers and physician offices.